The European Commission (EC) has granted marketing authorization for Boehringer Ingelheim’s Giotrif (afatinib) for the treatment of patients with advanced squamous cell carcinoma (SqCC) of the lung whose disease has progressed on or after treatment with platinum-based chemotherapy. The marketing authorization in Europe is valid for 28 countries within the EU. Afatinib is already approved for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).

Source: Boehringer Ingelheim